Delays fail to Quell Treg interest
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
Ash 2022 preview – Argenx’s expansion plans come into focus
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.